Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine in B-Lineage Non-Hodgkin Lymphoma
NCT05801913Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2023
- Primary completion
- Mar 2028
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19-CAR CMV-specific T-lymphocytes and Triplex in B-cell non-Hodgkin lymphoma, sponsored by City of Hope. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 15 years. Started Sep 2023; status: recruiting.
02
Drugs
anti-CD19-CAR CMV-specific T-lymphocytesTriplex
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05801913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801913.